Defining combination product CQAs across drug and device enables an end-to-end control strategy that improves product quality from the start of development.
- Does TSLP Inhibition Signal The Next Wave Of Respiratory Biologics?
- Nanosystems And Rare Diseases: Opportunities And Limitations
- 3 Emerging Trends In Drug Delivery Device Pipelines
- Organic Impurities: New Draft ICH Q3E Guidance For Leachables And Extractables
- Closing The Adherence Gap: The Connected Health Era
- Delivery Strategy For Next-Gen Cardiac Gene Therapies
- The Future Of Kidney Disease Therapeutics: Bringing Nanomedicine To Nephrology
- Injecting Cancer Killers: Intratumoral Therapy For Solid Tumors
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Stability Chambers: Testing, Equipment, And Uses
Performing stability studies is a critical step in the drug development process. Discover the ways to ensure that your drug is safe and effective as it goes to market.
-
Delivering On GLP-1 Demand: Combining Device And Supply Strategy
Meeting the demand for GLP-1 treatments requires robust and efficient delivery systems. Review how innovative solutions offer customization, streamlined manufacturing, and formulation compatibility.
-
Finding The Ideal Balance — Where Risk And Cost Of Quality Meet
It is a constant challenge to keep improving product value for customers while reducing overall costs. Part of the solution resides in the functional activities of the risk involved and the cost of quality management. This article delves further into the ideas behind finding the ideal balance of where risk and cost of quality meet.
-
Container Selection For A Highly Sensitive Drug Product: A Success Story
Learn about the importance of selecting the right container for sensitive drug products and how close collaboration is crucial for avoiding commercialization delays and safety risks to patients.
-
Functional Testing Summary Of Daikyo Crystal Zenith Nested Vials
The Daikyo Crystal Zenith nested vials meet the exterior dimensions of the glass standard ISO 8362-1. The vials maintain CCI for up to 6 months and can withstand ultra-cold temperatures and drop conditions.
-
Microphysiological Systems: Closing The Gap Between Models And Medicine
Microphysiological systems (MPS) use human cells to model tissue function, offering faster, more predictive insights for drug discovery, safety testing, and personalized medicine—bridging gaps left by animal and 2D models.
-
Liquid Capsule Manufacturing: What To Know
Capsules surround a drug in an unflavored, solid barrier enclosure. This article focuses on liquid capsule manufacturing and its advantages.
-
Simultaneous Spray Drying For Combination Dry Powder Inhaler Formulations
Three combination case studies are demonstrated, in which bevacizumab is paired with erlotinib, cisplatin, or paclitaxel in a dry powder inhaler formulation.
-
Capsule Formulation Development: From Dosage Forms To Filling
Capsules are tasteless and easy to take, offer streamlined development timelines, and simplicity of manufacturing. Discover capsule formulation development and the benefits of capsule dosage forms.
-
Successful Industrialization Requires Solid Foundations
Learn how choosing the appropriate quality of containment systems from the outset is critical to the successful industrialisation of an injectable drug product and review some of the associated challenges.
TOM'S TAKES ON DRUG DELIVERY
TALKING WITH TOM VIDEOCASTS
DELIVERED BY DEGRAZIO
-
6 Packaging And Delivery Challenges For Biologic Therapies
In this article, Fran DeGrazio identifies six aspects of biologics-based therapy packaging and delivery that, if addressed, may help to ensure successful product development and lifecycle management. They include 1) chemical compatibility with device functionality, 2) long-acting formulations, 3) product stability, 4) primary packaging and device integration, 5) cold storage, and 6) higher concentrations and viscosities.

